5 July 2018

In Clinical Infectious Diseases Elin Svensson and colleagues showed that increasing rifampicin exposure shortened the time needed to reach undetectable levels of bacteria in sputum. The effect did not plateau within the studied range of exposures, indicating that doses higher than 35 mg/kg could be yet more effective.

Abstract
Background. Tuberculosis remains a huge public health problem and the prolonged treatment duration obstructs effective tuberculosis control. Higher rifampicin doses have been associated with better bactericidal activity, but optimal dosing is uncertain. This analysis aimed to characterize the relationship between rifampicin plasma exposure and treatment response over 6 months in a recent study investigating the potential for treatment shortening with high-dose rifampicin.
 
Methods. Data were analyzed from 336 patients with pulmonary tuberculosis (97 with pharmacokinetic data) treated with rifampicin doses of 10, 20, or 35 mg/kg. The response measure was time to stable sputum culture conversion (TSCC). We derived individual exposure metrics with a previously developed population pharmacokinetic model of rifampicin. TSCC was modeled using a parametric time-to-event approach, and a sequential exposure-response analysis was performed.
 
Results. Higher rifampicin exposures increased the probability of early culture conversion. No maximal limit of the effect was detected within the observed range. The expected proportion of patients with stable culture conversion on liquid medium at week 8 was predicted to increase from 39% (95% confidence interval, 37%–41%) to 55% (49%–61%), with the rifampicin area under the curve increasing from 20 to 175 mg/L·h (representative for 10 and 35 mg/kg, respectively). Other predictors of TSCC were baseline bacterial load, proportion of culture results unavailable, and substitution of ethambutol for either moxifloxacin or SQ109.
 
Conclusions. Increasing rifampicin exposure shortened TSCC, and the effect did not plateau, indicating that doses >35 mg/kg could be yet more effective. Optimizing rifampicin dosage while preventing toxicity is a clinical priority.
 
Publication
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R.

Elin Svensson , Rob Aarnoutse , Lindsey te Brake and Martin Boeree are members of theme Infectious diseases and global health.

Related news items


Vierdaagse (Four Days Marches) 2020 call for projects

24 February 2020

Researchers pay attention! The Dutch Research Council (NWO) is looking for researchers to contribute to its outreach festival Expeditie Next, which will have an area at the Four Days Marches party (Vierdaagsefeesten).

read more

Dutch Brain Foundation grant for EENnacoma

20 February 2020

Lavrijsen and Van Erp: ‘This grant will facilitate practice-based research, professionalization and further academization of EENnacoma, and links between different health care and research institutions all for the benefit of people with prolonged disorders of consciousness and their families.'

read more

RIHS Awards Ceremony five winners

19 February 2020

On 18 February the RIHS 'Koek & Zopie' event took place. In front of an audience of more than 125 colleagues, RIHS awardees accepted their awards for the best PhD thesis, the research product with the highest impact on society, the best peer-reviewed publication and the Supervisor of the year 2019.

read more

Lowlands Science call for projects

17 February 2020

Researchers pay attention! Lowlands is looking for research teams to participate in Lowlands Science 2020. It’s a great way to reach a large audience, do unique experiments with and on them, and to have a memorable experience with your colleagues.

read more

Health Valley 10 - 11 - 12 March

13 February 2020

For three days, professionals from healthcare, health innovation, business, education and science will come together to share their knowledge and experiences about the healthcare of the future.

read more

KNAW Early Career Award for Geert Litjens

13 February 2020

Twelve young researchers received the Early Career Award from KNAW on 4 february. One of them is RIHS researcher Geert Litjens. The Award is aimed at researchers in the Netherlands at the start of their career who are capable of developing innovative and original research ideas.

read more